Dobutamine

<table>
<tr><td>Form</td><td>250mg per 20ml vial</td></tr>
<tr><td>Reconstitution</td><td>Already in solution
Dilute further before administration</td></tr>
<tr><td>Compatibility & Stability</td><td>Sodium Chloride 0.9%
Glucose 5%
Hartmann’s Solution</td></tr>
<tr><td>Administration</td><td><u>Continuous IV infusion</u>
Peripheral administration via a large vein:
Recommended concentration: 1mg/ml.
If clinically indicated a concentration of 2mg/ml may be used.
To prepare a 1mg/ml solution: Withdraw 40mls from a 500ml infusion bag of compatible fluid. Add 500mg (40mls) Dobutamine to the remaining 460ml.
Infusion rate in ml per hour (ml/hr) is:
<table><tr><th>Dose microgram/ kg/min</th><th colspan="12">Weight (Kg)</th></tr><tr><td></td><td>45</td><td>50</td><td>55</td><td>60</td><td>65</td><td>70</td><td>75</td><td>80</td><td>85</td><td>90</td><td>95</td><td>100</td></tr><tr><td>2.5</td><td>6.8</td><td>7.5</td><td>8.3</td><td>9</td><td>9.8</td><td>10.5</td><td>11.3</td><td>12.0</td><td>12.8</td><td>13.5</td><td>14.3</td><td>15.0</td></tr><tr><td>5.0</td><td>13.5</td><td>15.0</td><td>16.5</td><td>18.0</td><td>19.5</td><td>21.0</td><td>22.5</td><td>24.0</td><td>25.5</td><td>27.0</td><td>28.5</td><td>30.0</td></tr><tr><td>7.5</td><td>20.3</td><td>22.5</td><td>24.8</td><td>27.0</td><td>29.3</td><td>31.5</td><td>33.8</td><td>36.0</td><td>38.3</td><td>40.5</td><td>42.8</td><td>45.0</td></tr><tr><td>10</td><td>27.0</td><td>30.0</td><td>33.0</td><td>36.0</td><td>39.0</td><td>42.0</td><td>45.0</td><td>48.0</td><td>51.0</td><td>54.0</td><td>57.0</td><td>60.0</td></tr></table>To prepare a 2mg/ml solution: Withdraw 80mls from a 500ml infusion bag of compatible.
Add 1000mg (80mls) Dobutamine to the remaining 420ml.
Infusion rate in ml per hour (ml/hr) is:
<table><tr><th>Dose microgram/ kg/min</th><th colspan="12">Weight (Kg)</th></tr><tr><td></td><td>45</td><td>50</td><td>55</td><td>60</td><td>65</td><td>70</td><td>75</td><td>80</td><td>85</td><td>90</td><td>95</td><td>100</td></tr><tr><td>2.5</td><td>3.4</td><td>3.8</td><td>4.1</td><td>4.5</td><td>4.9</td><td>5.3</td><td>5.6</td><td>6.0</td><td>6.4</td><td>6.8</td><td>7.1</td><td>7.5</td></tr><tr><td>5.0</td><td>6.8</td><td>7.5</td><td>8.3</td><td>9.0</td><td>9.8</td><td>10.5</td><td>11.3</td><td>12.0</td><td>12.8</td><td>13.5</td><td>14.3</td><td>15.0</td></tr><tr><td>7.5</td><td>10.1</td><td>11.3</td><td>12.4</td><td>13.5</td><td>14.6</td><td>15.8</td><td>16.9</td><td>18.0</td><td>19.1</td><td>20.3</td><td>21.4</td><td>22.5</td></tr><tr><td>10</td><td>13.5</td><td>15.0</td><td>16.5</td><td>18.0</td><td>19.5</td><td>21.0</td><td>22.5</td><td>24.0</td><td>25.5</td><td>27.0</td><td>28.5</td><td>30.0</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>Central administration: See HDU guidelines for administration via central venous access device using a syringe pump.</td></tr>
<tr><td>Extravasation</td><td>Administer via a central venous access device if possible. The infusion has a low pH and extravasation is likely to cause tissue damage. May also cause vasoconstriction which can result in peripheral ischaemia at the infusion site when given peripherally.</td></tr>
</table>

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from pharmacy on 22142 or 22546.

Owner Virginia Silvari, Miriam Flynn Pharmacy Department CUH, Version 1 Updated November 2022.

Notes	• It is recommended that treatment with dobutamine should be discontinued gradually. • Solution may turn pink due to oxidation of the drug. There is no significant loss of potency during recommended storage and administration periods. • Continuous ECG and BP monitoring is recommended • Monitor heart rate and rhythm, arterial blood pressure, blood glucose, urine output, serum potassium and infusion rate.

Information provided relates to Dobutamine manufactured by Mercury Pharma.